Tela Bio Q3 2026 Results: Net Loss of $9.3M, Loss Widens
TELA Bio reported a net loss of $32.8 million for the nine months ended September 30, 2026, as revenue declined slightly to $57.3 million from $59.4 million in the prior year. A significant balance sheet shift occurred as $56.3 million in debt was reclassified to current liabilities, contributing to a total stockholders' deficit of $24.6 million.
- Key figure
- Net loss $9.3M